XNYS · Medical Devices
Last stored close · Nov 9, 2026
Close · Nov 9, 2026
$102.79+0.97%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
62/100
Positive
Score components
TickerWhale View
Medtronic scores 62 out of 100 overall, which we rate positive. Technical is its strongest area and Risk its weakest.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
- Risk
Quality & growth
30%52Moderate
- Revenue growth 9.8%
- EPS growth 12.1%
Valuation
25%65Positive
- P/E 25.3
- EV/Sales 4.2
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
#94 by market cap in our coverage · ~95,000 employees · Listed 1972-06-01 · www.medtronic.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#42 / 139sector rank by TickerWhale Score
TickerWhale Score 62 vs sector average 54.6 (+7.4)
Revenue growth (industry)Top 56%
Gross margin (industry)Top 56%
Return on equity (industry)Top 56%
P/E (industry)Cheaper than 87%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
91/100Strong vs universe
Ranks 91st of 100 covered names on our technical composite — the composite itself scores 81/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
5 buy · 1 sell · 2 neutral of 8 votes
TickerWhale rates MDT's technical setup strong — 91st percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+16.5%
- vs 50-day+10.6%
Momentum
Mixed
- RSI (14)65 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength31· trending
- MACD (12,26,9)buy(histogram 0.737)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 1 sell · 2 neutral.
Result — 5 buy vs 1 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-09 · revised_latestValuation multiples
- P/E (TTM)25.3
- P/S (TTM)3.5
- P/B2.6
- EV/EBITDA—
- EV/Sales4.2
- PEG2.08
Profitability & returns
- Gross margin65.0%
- Net margin13.9%
- ROE10.5%
- Debt/Equity0.56
Growth
- Revenue growth (YoY)9.8%
- EPS growth (YoY)12.1%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $132.1B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Apr '26 | Apr '25 | Apr '24 |
|---|---|---|---|
| Revenue | $36.4B | $33.5B | $32.4B |
| Gross profit | $23.6B | $21.9B | $21.1B |
| Operating income | $6.5B | $6.0B | $5.1B |
| Net income | $4.8B | $4.7B | $3.7B |
| EPS (diluted) | $3.73 | $3.61 | $2.76 |
| Free cash flow | $5.4B | $5.2B | $5.2B |
| Cash | $1.9B | $2.2B | $1.3B |
| Total debt | $28.0B | $28.5B | $25.0B |
| Equity | $49.5B | $48.0B | $50.2B |
| Net debt | $26.0B | $26.3B | $23.7B |
| Debt / equity | 0.57 | 0.59 | 0.50 |
| Liabilities / assets | 0.46 | 0.47 | 0.44 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: DAL →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDTCurrentMedtronic | 62 | 81 | 25.3 | — | 2.6 | 4.2 | $102.79 | +0.97% | +9.8% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 82 | 102.1 | — | 12.6 | 9.7 | $98.76 | +5.22% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.8 | — | 5.2 | 1.6 | $289.00 | +2.00% | +7.5% | ||
| EXELExelixis | 77 | 89 | 21.6 | — | 10.1 | 7.5 | $71.74 | +3.12% | +9.2% | ||
| TGTXTG Therapeutics | 77 | 85 | 22.6 | — | 16.5 | 12.8 | $63.38 | +5.94% | +76.1% | ||
| OSCROscar Health Inc - | 74 | 66 | 19.5 | — | 5.2 | 0.5 | $32.14 | +4.86% | +43.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.